Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 13M | 7M | 5M |
| Gross Profit | 12M | 6M | 4M |
| Operating Income | -81M | -70M | -38M |
| EBITDA | -80M | -65M | -33M |
| Net Income | -69M | -67M | -34M |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$24.05
+2.08% today
Window Change
+11.47%
Window
Nov 6, 2025 → Jun 22, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 154 bars · Nov 6, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Evommune, Inc. (EVMN) is a Healthcare stock with a market cap of $310.00M and listed on NYSE. The stock last traded around $24.05 and up 11.5% across the available one-year price window (Nov 6, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of +85.7%, EPS growth of +4.0%, a dividend yield of 0.0%. What stands out right now is revenue +85.7%, EPS +4.0%, free cash flow -31.6% with operating margin -623.6% and ROIC -39.0%. Valuation already assumes a fairly strong business story at price/sales 23.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines EVMN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EVMN
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EVMN Max Drawdown
-37.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for EVMN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.0M
-28.6% YoY
FY Net Income
-$34.1M
+49.0% YoY
Free Cash Flow
-$30.1M
+48.4% YoY
Revenue Growth
+85.7%
EPS Growth
+4.0%
Gross Margin
89.3%
Net Margin
-529.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 13M | 7M | 5M |
| Gross Profit | 12M | 6M | 4M |
| Operating Income | -81M | -70M | -38M |
| EBITDA | -80M | -65M | -33M |
| Net Income | -69M | -67M | -34M |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash & Equivalents | 44M | 16M | 29M |
| Total Assets | 225M | 76M | 82M |
| Total Liabilities | 19M | 220M | 160M |
| Shareholder Equity | 206M | -144M | -78M |
| Total Debt | 2M | 193M | 151M |
| Net Debt | -42M | 177M | 122M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
30M
+48.5% YoY
Capital Expenditures
118K
-34.1% YoY
Free Cash Flow
30M
+48.4% YoY
Key ratios
Gross Margin
89.3%
Operating Margin
-623.6%
Net Margin
-529.8%
ROE
89.7%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.